Dyax Corp. (Nasdaq: DYAX) 13.7% LOWER; reports the decision to discontinue the Companys Phase 2 trial investigating ecallantide in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE